| Clinical data | |
|---|---|
| Other names | 3-Methylene-7α-methylethinylestradiol; 3-Methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H30O |
| Molar mass | 310.481 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ERA-63, also known asORG-37663, as well as3-methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol, is asynthetic,steroidalestrogen and aselectiveagonist of theERα that was under development for the treatment ofrheumatoid arthritis but was never marketed.[2][1] The drug produced estrogenic effects but failed to showeffectiveness for rheumatoid arthritis in aphase IIaclinical study.[3][4] A large clinical trial also found thatprinaberel (ERB-041), a selectiveERβ agonist, was ineffective in the treatment of rheumatoid arthritis in spite of activity inpreclinicalmodels.[4]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |